p.141 抽出テキスト

locity predicts all-cause mortality and cardiovascular events in patients with diabetes: The Kyushu Prevention Study of Atherosclerosis. Diabetes Care 2014; 37: 2383-2390. PMID: 24898302 250. Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25. PMID: 17093942 251. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. PMID: 9742977 252. Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Med 2012; 9: e1001204. PMID: 22509138 253. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. PMID: 23992601 254. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335. PMID: 23992602 255. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242. PMID: 26052984 256. Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321: 69-79. PMID: 30418475 257. Morris PB, Ference BA, Jahangir E, et al. Cardiovascular Effects of Exposure to Cigarette Smoke and Electronic Cigarettes: Clinical Perspectives From the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol 2015; 66: 1378-1391. PMID: 26383726 258. Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002; 346: 506-512. PMID: 11844853 259. Ding N, Sang Y, Chen J, et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. J Am Coll Cardiol 2019; 74: 498-507. PMID: 31345423 260. Agarwal S. The association of active and passive smoking with peripheral arterial disease: results from NHANES 1999-2004. Angiology 2009; 60: 335-345. PMID: 19153101 261. Lu L, Mackay DF, Pell JP. Secondhand smoke exposure and intermittent claudication: a Scotland-wide study of 4231 non-smokers. Heart 2013; 99: 1342-1345. PMID: 23872592 262. Lu L, Mackay DF, Pell JP. Association between level of exposure to secondhand smoke and peripheral arterial disease: Cross-sectional study of 5,686 never smokers. Atherosclerosis 2013; 229: 273-276. PMID: 23880175 263. He Y, Lam TH, Jiang B, et al. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation 2008; 118: 1535-1540. PMID: 18809795 264. Young JC, Paul NJ, Karatas TB, et al. Cigarette smoking intensity informs outcomes after open revascularization for peripheral artery disease. J Vasc Surg 2019; 70: 1973-1983. PMID: 31176638 265. Amrock SM, Abraham CZ, Jung E, et al. Risk Factors for Mortality Among Individuals With Peripheral Arterial Disease. Am J Cardiol 2017; 120: 862-867. PMID: 28734461 266. Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004; 40: 1158-1165. PMID: 15622370 267. Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: A randomized controlled trial. J Am Coll Cardiol 2010; 56: 2105- 2112. PMID: 21144971 268. US Department of Health and Human Services. Treating Tobacco Use and Dependence: 2008 Update. 2008. 269. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012: CD000146. PMID: 23152200 270. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010; 121: 221-229. PMID: 20048210 271. Gorin SS, Heck JE. Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev 2004; 13: 2012-2022. PMID: 15598756 272. Hirakata H, Nitta K, Inaba M, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Apher Dial 2012; 16: 387- 435. PMID: 23046367 273. Watanabe Y, Kawanishi H, Suzuki K, et al. Japanese society for di-

alysis therapy clinical guideline for “Maintenance hemodialysis: hemodialysis prescriptions”. Ther Apher Dial 2015; 19 Suppl: 67-92. PMID: 25817933 274. Morooka H, Tanaka A, Inaguma D, et al. Peripheral artery disease at the time of dialysis initiation and mortality: a prospective observational multicenter study. BMJ Open 2020; 10: e042315. PMID: 33384396 275. Anantha-Narayanan M, Sheikh AB, Nagpal S, et al. Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis. Am J Nephrol 2020; 51: 527-533. PMID: 32570255 276. Iida O, Nakamura M, Yamauchi Y, et al. OLIVE Investigators. 3-Year Outcomes of the OLIVE Registry, a Prospective Multicenter Study of Patients With Critical Limb Ischemia: A Prospective, Multi-Center, Three-Year Follow-Up Study on Endovascular Treatment for Infra-Inguinal Vessel in Patients With Critical Limb Ischemia. JACC Cardiovasc Interv 2015; 8: 1493-1502. PMID: 26404203 277. Nakano M, Hirano K, Iida O, et al. Clinical efficacy of infrapopliteal endovascular procedures for hemodialysis patients with critical limb ischemia. Ann Vasc Surg 2015; 29: 1225-1234. PMID: 26004963 278. Kumada Y, Nogaki H, Ishii H, et al. Clinical outcome after infrapopliteal bypass surgery in chronic hemodialysis patients with critical limb ischemia. J Vasc Surg 2015; 61: 400-404. PMID: 25441673 279. Suematsu N, Iida O, Takahara M, et al. Prognostic Factors in Hemodialysis Patients Undergoing Endovascular Treatment for Critical Limb Ischemia due to Isolated Below-the-Knee Disease. J Atheroscler Thromb 2015; 22: 404-414. PMID: 25346201 280. Yuo TH, Wallace JR, Fish L, et al. Editor’s Choice - Comparison of Outcomes After Open Surgical and Endovascular Lower Extremity Revascularisation Among End Stage Renal Disease Patients on Dialysis. Eur J Vasc Endovasc Surg 2019; 57: 248-257. PMID: 30385187 281. Higashitani M, Uemura Y, Mizuno A, et al. Toma-Code Registry Investigators. Cardiovascular Outcome and Mortality in Patients Undergoing Endovascular Treatment for Symptomatic Peripheral Artery Disease: Short-Term Results of the Toma-Code Registry. Circ J 2018; 82: 1917-1925. PMID: 29760308 282. Ureña P, Malergue MC, Goldfarb B, et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999; 20: 217-225. PMID: 10480155 283. Ohtake T, Oka M, Ikee R, et al. Impact of lower limbs’ arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg 2011; 53: 676-683. PMID: 21211928 284. Fukagawa M, Yokoyama K, Koiwa F, et al. CKD-MBD Guideline Working Group. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17: 247-288. PMID: 23735142 285. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277. PMID: 23870817 286. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233. PMID: 19713308 287. Elango K, Javaid A, Khetarpal BK, et al. The Effects of Warfarin and Direct Oral Anticoagulants on Systemic Vascular Calcification: A Review. Cells 2021; 10: PMID: 33807457 288. Ishii H, Aoyama T, Takahashi H, et al. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J Cardiol 2016; 67: 199-204. PMID: 26074442 289. Hidaka S, Kobayashi S, Iwagami M, et al. Sarpogrelate hydrochloride, a selective 5-HT2A receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease. Ren Fail 2013; 35: 43-48. PMID: 23110683 290. Ohtake T, Sato M, Nakazawa R, et al. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Ther Apher Dial 2014; 18: 1-8. PMID: 24499078 291. Matsuura R, Hidaka S, Ohtake T, et al. Intradialytic hypotension is an important risk factor for critical limb ischemia in patients on hemodialysis. BMC Nephrol 2019; 20: 473. PMID: 31856757 292. O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the

risk of lower extremity peripheral arterial disease: Results from the